Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
IPO Year:
Exchange: NYSE
Website: labcorp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/30/2024 | Hold → Buy | HSBC Securities | |
| 10/1/2024 | $235.00 | Neutral | Piper Sandler |
| 3/25/2024 | $250.00 | Hold → Buy | Argus |
| 2/26/2024 | $260.00 | Outperform | Leerink Partners |
| 2/9/2024 | $240.00 | In-line | Evercore ISI |
| 1/3/2024 | $222.00 | Equal Weight | Barclays |
| 9/6/2023 | $210.00 | Hold | HSBC Securities |
| 12/12/2022 | $275.00 → $250.00 | Buy → Neutral | Citigroup |
| 9/19/2022 | Buy → Hold | Argus | |
| 8/22/2022 | $300.00 | Overweight | Morgan Stanley |
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
FWP - LABCORP HOLDINGS INC. (0000920148) (Subject)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov
SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w
Health system executive brings three decades of medical enterprise experience to Labcorp BURLINGTON, N.C., June 7, 2023 /PRNewswire/ -- Labcorp (NYSE:LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent member. Dr. Rothman's appointment is effective June 6, 2023, at which time the Board will expand to 12 directors, 11 of whom are independent. "I am pleased to announce Dr. Rothman's appointment to our Board of Directors," said Adam Schechter, chairman and chief executive officer (CEO) of Lab
Labcorp (NYSE:LH), a leading global life sciences company, today announced that Kirsten Kliphouse, president of Americas, Google Cloud, has joined its Board of Directors as an independent member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221013006001/en/Photo courtesy of Labcorp Kliphouse brings decades of leadership experience honed at some of the world's most-recognizable technology companies, as well as a proven passion for building teams and customer relationships. At Google Cloud, Kliphouse is focused on harnessing technology and the collective power of her teams to help enterprises, mid-market customers, and small and
Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005164/en/Victor Lobanov, Ph.D., Ventus Senior Vice President, Head of Computational Sciences (Photo: Business Wire) Dr. Lobanov brings to Ventus more than 25 years of experience in developing and implementing leading-edge computational methods across the d
After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Gabriela Perez as Chief Commercial Officer. In her new role, Perez will oversee Big Health's global commercial growth and strategy, including sales, client management, strategic partnerships, and new markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203005297/en/Big Health Chief Commercial Office
BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, to serve on its Board of Directors effective immediately. Dr. Eisenberg has extensive experience with forensic DNA testing, biotechnology, molecular genetics and molecular oncology. She has helped lead the development and validation of well over a thousand clinical assays used for patient care during her more than 30-year tenure at Labcorp (NYSE: LH), a global life sciences company. Dr. Eisenberg previously held roles on the Nat
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
Collaboration to leverage Praia Health's technology and Labcorp's comprehensive testing capabilities to streamline and personalize patient experience Praia Health, the consumer experience orchestration platform for health systems, is pleased to announce it has secured a strategic investment from the Labcorp Venture Fund and will collaborate with Labcorp, a global leader of innovative and comprehensive laboratory services, to streamline and personalize the patient experience for lab orders and testing within select health systems. "Our collaboration with Labcorp represents a significant step forward in delivering personalized and seamless healthcare experiences," said Justin Dearborn, CEO
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiativesBURLINGTON, N.C., Oct. 24, 2024 /PRNewswire/ -- Labcorp
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
As syphilis cases surge nationwide, the collaboration will bring the First To Know® over-the-counter test to clinicians and patients across professional and hospital settings NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that Labcorp, a global leader of innovative and comprehensive laboratory services, will be the exclusive U.S. distributor of its First To Know® Syphilis Test in professional and healthcare settings. Through Labcorp's extensive distribution network and trusted presence in clinical settings, this collaboration will expand access to the syphilis test that provides results in 15 minutes with as lit
Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide BURLINGTON, N.C., Oct 10, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today it has expanded its portfolio of sexually transmitted infection (STI) testing options to include the First to Know® Syphilis Test, the first over-the-counter blood test granted market authorization by the U.S. Food & Drug Administration (FDA) that can be performed by both physicians and patients.
BURLINGTON, N.C., Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident de
Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served
BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also
New solution is the first holistic program available in a digital app to help women manage the postpartum period BOSTON, Sept. 18, 2024 /PRNewswire/ -- Ovia Health by Labcorp (Ovia) today announced the expansion of its women's health solutions to include a personalized, comprehensive Postpartum Experience – a 12-month program designed to help women manage multiple aspects of the postpartum period through personalized recovery modes, symptom tracking and alerts, and mental health support. For employers or health plans interested in offering Ovia as a benefit, for more informati
Updates Full-Year Guidance Results from Continuing Operations for third quarter 2024 versus last year:Revenue: $3.28 billion versus $3.06 billionDiluted EPS: $2.00 versus $2.11Adjusted EPS: $3.50 versus $3.38Free Cash Flow: $162 million versus $171 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.6% to 7.3%; midpoint unchangedAdjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15Free Cash Flow of $850 million to $980 millionAnnounced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiativesBURLINGTON, N.C., Oct. 24, 2024 /PRNewswire/ -- Labcorp
BURLINGTON, N.C., Oct. 10, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on December 13, 2024, to stockholders of record as of the close of business on November 26, 2024. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident de
BURLINGTON, N.C., Sept. 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2024 before the market opens on Thursday, October 24, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also
Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year:Revenue: $3.22 billion versus $3.03 billionDiluted EPS: $2.43 versus $1.74Adjusted EPS: $3.94 versus $3.42Free Cash Flow: $432.9 million versus $58.2 millionUpdated Full-Year 2024 Guidance:Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0%Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 millionShare repurchase authorization increased by $1.0 billion to $1.4 billionLaunched important new tests in specialty testing areasIntroduced Labcorp Global Trial Connect, a suite
BURLINGTON, N.C., July 25, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 13, 2024, to stockholders of record as of the close of business on August 29, 2024. About Labcorp Labcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident de
BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 1, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also re
Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year:Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7%Diluted EPS: $2.69 versus $2.34Adjusted EPS: $3.68 versus $3.46Full-Year 2024 Guidance: Raised midpoint and narrowed range of adjusted EPS to $14.45 to $15.35; Free Cash Flow remains $1.00 billion to $1.15 billionYear to date announced/completed five acquisitions that support our strategySignificantly expanded our test menu in key therapeutic areasBURLINGTON, N.C., April 25, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced results for the
BURLINGTON, N.C., April 11, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 12, 2024, to stockholders of record as of the close of business on May 28, 2024. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.
BURLINGTON, N.C., March 27, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participants may also r
Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year:Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billionDiluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66Free Cash Flow: Q4 of $414.2 million vs $508.1 million; Full year of $748.7 million vs $1.34 billionAnnounced six new laboratory partnerships and launched new innovative tests in our focused specialty areas across the business in 2023Full Year 2024 Guidance: Adjusted EPS of $14.30 to $15.40 and Free Cash Flow of $1.00 billion to $1.15 billionBURLINGTON,
HSBC Securities upgraded Labcorp Holdings Inc. from Hold to Buy
Piper Sandler initiated coverage of Labcorp Holdings Inc. with a rating of Neutral and set a new price target of $235.00
Argus upgraded Laboratory Corp from Hold to Buy and set a new price target of $250.00
Leerink Partners initiated coverage of Laboratory Corp with a rating of Outperform and set a new price target of $260.00
Evercore ISI initiated coverage of Laboratory Corp with a rating of In-line and set a new price target of $240.00
Barclays initiated coverage of Laboratory Corp with a rating of Equal Weight and set a new price target of $222.00
HSBC Securities initiated coverage of Laboratory Corp with a rating of Hold and set a new price target of $210.00
Citigroup downgraded Laboratory Corp from Buy to Neutral and set a new price target of $250.00 from $275.00 previously
Argus downgraded Laboratory Corp from Buy to Hold
Morgan Stanley resumed coverage of Laboratory Corp with a rating of Overweight and set a new price target of $300.00
- Reuters
-Reuters
Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Holdings (NYSE:LH) with a In-Line and raises the price target from $210 to $215.
Funds To Accelerate Development And Expansion Of At-Home Diagnostic Solutions; Investors Include Labcorp Venture Fund And Kompass Kapital Management
In the last three months, 6 analysts have published ratings on Labcorp Holdings (NYSE:LH), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 1 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $245.67, a high estimate of $261.00, and a low estimate of $213.00. Experiencing a 3.91% decline, the current average is n
Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $258 to $261.
Across the recent three months, 4 analysts have shared their insights on Labcorp Holdings (NYSE:LH), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 1 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Labcorp Holdings, presenting an average target of $238.75, a high estimate of $255.00, and a low estimate of $213
JP Morgan analyst Lisa Gill maintains Labcorp Holdings (NYSE:LH) with a Overweight and lowers the price target from $261 to $243.
Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseasesKey milestone reached in Invitae's Chapter 11 processBURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae."As a leading medical genetics company, Invitae has advanced genomics-based testing solutions across its network," said Mark Schroeder, Executive Vice President and President of Diagnostics
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)
SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)
SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)